| Probiodrug–Crossbeta Biosciences: biomarker research, 201712– collab extension developm Alzheimer biomarker to support Probiodrug’s clinical program |
2017-12-05 |
| Probiodrug–MC Services: public relations, 201712 service existent by MC Services |
2017-12-05 |
| Probiodrug–Optimum Strategic Communications: public relations, 201712 service existent by Optimum |
2017-12-05 |
| Probiodrug–Trout Group: public relations, 201712 service existent by The Trout Group |
2017-12-05 |
| Arrowhead–Silence Therapeutics: investment, 201712 DIVESTMENT 2.036m common shares for $7.5m w realised profit of $4.1m |
2017-12-04 |
| Evotec–Ncardia: drug discovery technology, 201712– license ww non-excl €na to access iPSC-derived disease models of Ncardia |
2017-12-04 |
| Institut Virion\Sirion–ExpreS2ion Biotech: expression technology, 201712– collab using ExpreS2 platform for antigen production for IVD tests |
2017-12-04 |
| JnJ–Idorsia: aprocitentan, 201712– collab developm + license ww commerc for Janssen $230m upfront + royalties 20–35% |
2017-12-04 |
| Anaveon–Basel (govt): investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch |
2017-12-01 |
| Anaveon–SEVERAL: investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch |
2017-12-01 |
| Anaveon–Univ Zurich: investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch |
2017-12-01 |
| Roche–Confo Therapeutics: drug discovery services, 201712–202005 collab up to €87.5m plus milestones r+d + commerc small molecule GPCR agonists |
2017-12-01 |
| I-Mab–MorphoSys: antibody cancer drug, 201711– license excl Greater China for MOR202 with $20m upfront + $100m milestones + tiered 2-digit royalties |
2017-11-30 |
| Enyo Pharma–Charles River: drug discovery services, –201711 collab drug target identification of EYP002 using CCMS technology |
2017-11-28 |
| Bitkom–Bayer: digital economy, 201711 Bayer is member of Bitkom w particular focus on digital health + digital farming |
2017-11-27 |
| Boehringer–BioMed X: pharma research, 201711– collab new BioMed X research group in bacterial modulation of innate immunity |
2017-11-27 |
| Geneva Biotech–Sphere Fluidics: genomic technology, 201711– collab to develop large DNA cargo gene deliver + genome engineering systems |
2017-11-27 |
| LIMA project–EU (govt): grant, 201711– Horizon 2020 grant €6.3m 4y Liquid biopsies and IMAging for improved cancer care |
2017-11-23 |
| Arsanis–New Enterprise Associates: investment, 201711 private placement $20m with 2m shares common stock at $10/share |
2017-11-20 |
| Arsanis–SEVERAL: investment, 201711 IPO $46m with 4m+600k shares common stock at $10/share at Nasdaq Global Market |
2017-11-20 |
| Ncardia–SEVERAL: investment, 201711 financing round Series B €10.5m led by new investor Épimède |
2017-11-17 |
| Viewics–Roche: investment, 201711 acquisition of Viewics Inc by Roche |
2017-11-17 |
| High-Tech Gründerfonds–EWE: investment, 201711 € 7-figure investment in HTGF III fund by EWE AG |
2017-11-16 |
| Laboratoires Réunis–bio.logis: genetic software, 201711 supply use of bio.logis GIMS by Laboratoires Réunis |
2017-11-16 |
| United States (govt)–Molecular Health: drug safety software, 201711–202210 extension collab with CDER for additional 5 years |
2017-11-16 |
| Roche–Arvinas: protein degradation drugs, 201711– strategic license expansion for PROTAC technology to Genentech |
2017-11-15 |
| Xeltis–SEVERAL: investment, 201711 financing round Series C €45m led by a global strategic investor + incl Ysios Capital + LSP + Kurma Partners et al |
2017-11-15 |
| Bayer–Loxo Oncology: TRK inhibitors, 201711– ww collab $400m upfront + $650m milestones developm of larotectinib + LOXO-195 |
2017-11-14 |
| Scipio Bioscience–High-Tech Gründerfonds: investment, 201711 seed financing round totalling €1.2m from Quadrivium 1 Seed Fund + HTGF |
2017-11-14 |
| Scipio Bioscience–SEVERAL: investment, 201711 seed financing round €1.2m from Seventure Partners Quadrivium 1 Seed Fund + HTGF |
2017-11-14 |
| Caris Life Sciences–Qiagen: lab automation equipment, 201711 supply QIAsymphony system to Caris Life Sciences |
2017-11-13 |
| CRISPR Therapeutics–CureVac: mRNA technology, 201711– collab + license using RNArt techn to develop in-vivo gene-editing programs in liver diseases |
2017-11-13 |
| InflaRx–SEVERAL: investment, 201711 IPO $100m w 6.667m common shares at $15/share at Nasdaq Global Select Market |
2017-11-10 |
| Ono Pharmaceutical–Neurimmune: drug discovery services, 201711– collab finding mABs against target in neurodegenerative disease using RTM technology |
2017-11-09 |
| Boehringer–MiNA Therapeutics: RNAa drugs, 201711– collab up to €307m plus royalties developm of RNAa drugs for fibrotic liver diseases incl NASH |
2017-11-08 |
| MiNA Therapeutics–MacDougall Biomedical Communications: public relations, 201711 service existent by MacDougall |
2017-11-08 |
| NousCom–5AM Ventures: investment, 201711 financing round Series B totalling €42m incl new + co-investor 5AM Ventures |
2017-11-06 |
| NousCom–Abingworth: investment, 201711 financing round Series B totalling €42m incl new + lead investor Abingworth |
2017-11-06 |
| NousCom–Huntsworth: public relations, 201711 service existent by Citigate Dewe Rogerson |
2017-11-06 |
| NousCom–Life Sciences Partners: investment, 201711 financing round Series B totalling €42m incl returning co-investor LSP |
2017-11-06 |
| NousCom–SEVERAL: investment, 201711 financing round Series B €42m led by new investor Abingworth + incl 5AM Ventures + LSP + Versant Ventures |
2017-11-06 |
| NousCom–Versant Ventures: investment, 201711 financing round Series B totalling €42m incl returning co-investor Versant Ventures |
2017-11-06 |
| Boehringer–Dicerna Pharmaceuticals: RNAi drugs, 201711– collab up to $201m plus royalties developm of RNAi drugs for chronic liver diseases incl NASH |
2017-11-02 |
| Evolva–SEVERAL: investment, 201710 capital increase CHF21.1m private placement to Pictet Asset Management + Cologny Advisors at CHF0.31/share |
2017-11-02 |
| Evolva–SEVERAL: investment, 201710 capital increase CHF65m discounted right offering |
2017-11-02 |
| Topas Therapeutics–Boehringer: investment, 201711 extension of financing round Series A to €18m with €4m investment from BIVF |
2017-11-02 |
| Bluebird Bio–Merck (DE): contract manufacturing, 201711– collab long-term commercial manufacturing of lentiviral vector across all Bluebird programs |
2017-11-01 |
| Charles River–Caprotec: CCMS technology, 2017 acquisition of CCMS IP + technology of Caprotec by Charles River |
2017-11-01 |
| Ada Health–SEVERAL: investment, financing round €40m led by Access Industries (Len Blavatnik) |
2017-10-31 |
| BioGeneration Ventures–SEVERAL: investment, 201710 final closing of BGV III with €82m incl new investors BMS + JnJ + Schroder Adveq + MAN Pension |
2017-10-31 |
| Blue Ocean Nova–Endress+Hauser: investment, 201710 acquisition €na of Blue Ocean Nova AG |
2017-10-31 |
| Advanced Accelerator Applications–Novartis: investment, 201710–201801 cash tender offer $3.9b with $41/ordinary share |
2017-10-30 |
| Boehringer–Hospital Corp of America: clinical research, 201710– collab expansion clinical developm combi cancer treatments w Sarah Cannon |
2017-10-30 |
| Daiichi Sankyo–Glycotope: antibody-drug conjugates, 201710– option agreem €na for license + collab using Daiichi ADC technology with PankoMab-GEX |
2017-10-30 |
| Charles River–InSphero: preclinical cancer models, 201710– collab developm 3D InSight PDX Microtissues for iv oncology services |
2017-10-26 |
| Heidelberg ImmunoTherapeutics–Akampion: public relations, 201710 service existent by Akampion |
2017-10-26 |
| Phenex–Akampion: public relations, 201710 service existent by Akampion |
2017-10-26 |
| Provecs–Akampion: public relations, 201710 service existent by Akampion |
2017-10-26 |
| Tesaro–Evotec: drug discovery services, 201710– collab 3y €na r+d small-molecule candidates against I/O target |
2017-10-26 |
| JnJ–BioMed X: pharma research, 201710– collab up to five research projects in area of autoimmune disease w Janssen RnD LLC |
2017-10-25 |
| Fluidigm–Univ Zurich: mass cytometry s/w, 201710– ww distribution of histoCAT s/w with Hyperion Imaging System by Fluidigm |
2017-10-24 |
| ADC Therapeutics–SEVERAL: investment, 201710 financing round Series E $200m incl Auven Therapeutics + Wild Family Office + AstraZeneca |
2017-10-23 |
| Counsyl–Qiagen: genomic software tools, 201710 supply existent early customer of Qiagen Clinical Insight solution |
2017-10-19 |
| DCPrime–Apceth: contract manufacturing, 201710– supply service manufacturing of DCP-001 DC vaccine by Apceth Biopharma GmbH |
2017-10-19 |
| High-Tech Gründerfonds–RWE: investment, 201710 investment 7-digit € of RWE Generation SE in HTGF III Fund |
2017-10-19 |
| CureVac–Lilly: investment, 201710 equity investment $45m as part of mRNA cancer vaccines collaboration |
2017-10-18 |
| Lilly–CureVac: cancer vaccines, 201710– collab ww $50m upfront + $45m equity investment + $1.7b milestones up to 5 products using RNActive technology |
2017-10-18 |
| SurgVision–Bracco: investment, 201710 acquisition of SurgVision BV by Bracco Imaging SpA |
2017-10-18 |
| Weizmann Institute–Bruker: MRI system, 201710 supply Biospec 15.2 Tesla USR preclinical UHF MRI system |
2017-10-18 |
| Institut Nehring–Eurofins: investment, 201710 acquisition of Institut Nehring GmbH by Eurofins |
2017-10-16 |
| Roche–Warp Drive Bio: drug discovery, 201710– strategic collab up to $387m plus royalties r+d of novel antibiotics using Genome Mining platform |
2017-10-16 |
| Apeiron–MC Services: public relations, 201710 service existent by MC Services AG |
2017-10-13 |
| InflaRx–Bain Capital: investment, 201710 financing round Series D totalling $30m incl co-lead investor Bain Capital Life Sciences LP |
2017-10-13 |
| InflaRx–Cormorant Asset Management: investment, 201710 financing round Series D totalling $30m incl co-lead investor Cormorant |
2017-10-13 |
| InflaRx–RA Capital: investment, 201710 financing round Series D totalling $30m incl co-lead investor RA Capital Management LLC |
2017-10-13 |
| InflaRx–SEVERAL: investment, 201710 financing round Series D $55m capital increase co-led by Bain Capital LS + Cormorant + RA Capital |
2017-10-13 |
| Kohlberg Kravis Roberts–Eurofins: investment, 201710– acquisition of LGC Forensics division of LGC Group from KKR |
2017-10-12 |
| Nestlé–Codexis: therapeutic enzymes, 201710– collab strategic alliance using CodeEvolver platform + incl option for ww developm of CDX-6114 |
2017-10-12 |
| BIA Separations–Nuvonis: vaccine + gene therapy production technology, 201710– collab co-marketing of cell lines + purification technologies |
2017-10-10 |
| Bruker–Protea Biosciences: MS-based clinical tests, 201710– collab development clinical oncology screening assays on rapifleX MALDI Tissuetyper |
2017-10-10 |
| Medical Univ Innsbruck–Helmholtz: IP services, 201710– service collab knowledge + technology transfer with Ascenion GmbH |
2017-10-09 |
| Chiome Bioscience–Minapharm: GlymaxX technology, 201710– service + license cell line developm for antibody production applying GlymaxX by ProBioGen |
2017-10-05 |
| Boehringer–Siamab Therapeutics: antibody cancer drug, 201710– collab €na discovery of TACA selective targeting antibodies |
2017-10-04 |
| Immatics–Amgen: investment, 201710 financing round Series E totalling $58m incl Hopp + Strüngmann + Wellington Partners + Amgen et al |
2017-10-04 |
| Immatics–Hopp Group: investment, 201710 financing round Series E totalling $58m incl Hopp + Strüngmann + Wellington Partners + Amgen et al |
2017-10-04 |
| Immatics–SEVERAL: investment, 201710 financing round Series E $58m Hopp + Strüngmann + Wellington Partners + Amgen et al |
2017-10-04 |
| Immatics–Strüngmann Group: investment, 201710 financing round Series E totalling $58m incl Hopp + Strüngmann + Wellington Partners + Amgen et al |
2017-10-04 |
| Immatics–Wellington Partners: investment, 201710 financing round Series E totalling $58m incl Hopp + Strüngmann + Wellington Partners + Amgen et al |
2017-10-04 |
| Lunaphore–Redalpine: investment, 201710 2nd financing round totalling CHF6m incl existing investor Redalpine Venture Partners |
2017-10-04 |
| Lunaphore–SEVERAL: investment, 201710 2nd financing round CHF6m incl Redalpine + Zühlke Ventures + Polytech Ecosystem et al. |
2017-10-04 |
| Body Labs–Amazon: investment, 201710 acquisition €na (estimate $50m-$70m) of Body Labs by Amazon |
2017-10-03 |
| Cullinan Oncology–F2 Ventures: investment, 201710 financing round Series A totalling $150m incl co-lead investor F2 Ventures |
2017-10-03 |
| Cullinan Oncology–SEVERAL: investment, 201710 financing round Series A $150m co-led by UBS Oncology Impact Fund (MPM Capital) + F2 Ventures |
2017-10-03 |
| Cullinan Oncology–UBS: investment, 201710 financing round Series A totalling $150m incl co-lead investor UBS Oncology Impact Fund managed by MPM |
2017-10-03 |
| Epiontis–Precision Medicine Group: investment, 201709 acquistion of Epiontis GmbH |
2017-09-30 |
| Eppendorf–Arburg: plastic moulding machine, 201709 supply of 100th Allrounder machine to Eppendorf Polymere GmbH |
2017-09-29 |
| Exscientia–Evotec: investment, 201709 investment €15m by Evotec AG to acquire minority stake in Exscientia Ltd |
2017-09-28 |
| Novartis–Univ California: drug discovery technology, 201709– collab establishment of Novartis-Berkeley Center for Proteomics & Chemistry Technologies |
2017-09-28 |
| Orgentec–Streck: laboratory equipment, 201709– distribution of Streck cell stabilisation + molecular products by Orgentec SASA in France |
2017-09-28 |
| Merlin Diagnostika–Bruker: investment, 201709 acquisition €na by Bruker |
2017-09-26 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 19 20 21 ... 30 31 32 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
